Michael Secora - 13 Jun 2023 Form 4 Insider Report for RECURSION PHARMACEUTICALS, INC. (RXRX)

Role
Chief Financial Officer
Signature
/s/ Jonathan Golightly, attorney-in-fact
Issuer symbol
RXRX
Transactions as of
13 Jun 2023
Transactions value $
-$333,645
Form type
4
Filing time
15 Jun 2023, 19:28:58 UTC
Previous filing
17 May 2023
Next filing
19 Jul 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RXRX Class A Common Stock Options Exercise $83.3K +37.5K +4.73% $2.22 830K 13 Jun 2023 Direct F1, F2
transaction RXRX Class A Common Stock Sale -$248K -25K -3.01% $9.93 805K 13 Jun 2023 Direct F1, F3
transaction RXRX Class A Common Stock Options Exercise $83.3K +37.5K +4.66% $2.22 843K 14 Jun 2023 Direct F1
transaction RXRX Class A Common Stock Sale -$252K -25K -2.97% $10.07 818K 14 Jun 2023 Direct F1, F4

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction RXRX Stock Option (Right to Buy) Options Exercise $0 -37.5K -4.57% $0.00 783K 13 Jun 2023 Class A Common Stock 37.5K $2.22 Direct F1, F5
transaction RXRX Stock Option (Right to Buy) Options Exercise $0 -37.5K -4.79% $0.00 745K 14 Jun 2023 Class A Common Stock 37.5K $2.22 Direct F1, F5
holding RXRX Stock Option (Right to Buy) 1.5M 13 Jun 2023 Class A Common Stock 0 $2.22 Direct F5
holding RXRX Stock Option (Right to Buy) 117K 13 Jun 2023 Class A Common Stock 0 $11.14 Direct F6
holding RXRX Stock Option (Right to Buy) 3.91K 13 Jun 2023 Class A Common Stock 0 $11.14 Direct
holding RXRX Stock Option (Right to Buy) 405K 13 Jun 2023 Class A Common Stock 0 $8.55 Direct F7
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 Transaction is pursuant to a 10b5-1 trading plan adopted by the Reporting Person on March 1, 2023.
F2 Includes 2,754 shares purchased pursuant to the Issuer's Employee Stock Purchase Plan on May 22, 2023.
F3 This transaction was executed in multiple trades at prices ranging from $9.59 to $10.18. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F4 This transaction was executed in multiple trades at prices ranging from $9.63 to $10.44. The price reported above reflects the weighted average sale price. The Reporting Person undertakes to provide upon request by the staff of the Securities and Exchange Commission, the Issuer, or a security holder of the Issuer, full information regarding the number of shares sold at each separate sale price.
F5 The option, originally for 1,500,000 shares, vested as to one forty-eighth (1/48th) of the shares subject to the award shall vest one month after March 1, 2020, or the Vesting Commencement Date, and one forty-eighth (1/48th) of the shares subject to the award shall vest each month thereafter on the same day of the month as the Vesting Commencement Date.
F6 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2022, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.
F7 The option vests as to one forty-eighth (1/48th) of the shares subject to the option on March 1, 2023, and one forty-eighth (1/48th) of the shares subject to the option shall vest each month thereafter.